Natalie Wilgoren
Psychiatric/Mental Health · Delray Beach, FLNPI 1316917347
Payments from drug & device makers
Across 41 payments — averaging $109.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$933
- Otsuka America Pharmaceutical, Inc.$761
- AbbVie$444
- Johnson & Johnson$392
- Axsome Therapeutics, Inc.$354
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$350
- plus $1K from 7 others
What the payments were for
- Food & beverage$4,480100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $933 |
| Otsuka America Pharmaceutical, Inc. | 7 | $761 |
| AbbVie | 4 | $444 |
| Johnson & Johnson | 3 | $392 |
| Axsome Therapeutics, Inc. | 4 | $354 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $350 |
| E.r. Squibb & Sons, L.L.C. | 2 | $279 |
| Neurocrine Biosciences, Inc. | 2 | $252 |
| Alkermes, Inc. | 3 | $231 |
| Supernus Pharmaceuticals, Inc. | 1 | $124 |
| Vanda Pharmaceuticals Inc. | 1 | $124 |
| Noven Pharmaceuticals, Inc. | 1 | $123 |
| Livanova USA, Inc. | 1 | $112 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$833
- Austedo XR$555
- REXULTI$485
- CAPLYTA$350
- INVEGA SUSTENNA$286
- COBENFY$279
- INGREZZA$252
- ABILIFY MAINTENA$250
- VRAYLAR$247
- Auvelity$216
- ABILIFY ASIMTUFII$125
- SUNOSI$124
- QELBREE$124
- Fanapt$124
- Xelstrym$123
- VNS Therapy Symmetry Model 8103 Generator$112
- SPRAVATO$106
- UZEDY$102
How this compares
$4,480 in reported general payments places this provider in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,076 |
| Oxcarbazepine | 11 | $1,267 |
| Bupropion XlBupropion Hcl | 19 | $438 |
| Duloxetine Hcl | 17 | $435 |
| Doxepin Hcl | 11 | $263 |
| Lamotrigine | 12 | $226 |
| Trazodone Hcl | 21 | $178 |
| Clonazepam | 23 | $77 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Delray Beach
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Cheedy JajaTampa$266K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.